Develops oncolytic virus therapies for cancer treatment, focusing on immunotherapy and viral-based cancer therapies.
Oncolytics Biotech Inc., headquartered in Calgary, Canada, is a biopharmaceutical company in the developmental stages, dedicated to advancing innovative treatments for cancer. Founded in 1998, the company specializes in the discovery and development of pharmaceutical products aimed at addressing critical unmet needs in oncology.
Central to Oncolytics Biotech's portfolio is pelareorep, its lead product and an intravenously delivered immunotherapeutic agent designed for the treatment of both solid tumors and hematological malignancies. The company has entered into strategic co-development partnerships to further enhance pelareorep's potential. Notably, Oncolytics Biotech collaborates with Merck KGaA and Pfizer Inc. on developing pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody. This combination therapy targets hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer, aiming to improve treatment outcomes significantly.
In addition to its collaborations with industry leaders, Oncolytics Biotech works closely with PrECOG LLC to advance clinical research initiatives. These partnerships underscore the company's commitment to leveraging innovative approaches and collaborative efforts to accelerate the development of effective cancer therapies. Oncolytics Biotech continues to drive forward with its mission to make a meaningful impact on the lives of cancer patients globally through pioneering research and strategic partnerships.